novabay.com - שווי פירמה כולל NBY

NovaBay Pharmaceuticals (NBY) specializes in developing ophthalmological products for the therapy and hygiene of visual organs. Fierce competition from manufacturers of low-cost generics forces the company to invest in promotion, while the Enterprise Value stands at 42.92. This price chart reflects market expectations for a business that relies on the unique composition of the Avenova spray and direct supplies to physicians. Stability is ensured by a strong staff of biochemists and the strategic selection of sales representatives.

NovaBay Pharmaceuticals generates revenue through the sale of specialized antiseptics and cosmetic products via pharmacy chains. Distribution efficiency directly impacts liquidity, adjusting the final business valuation. Enterprise Value aggregates market capitalization and debt, subtracting cash to determine the actual acquisition price of the company. This indicator reflects the balance between leveraged capital and assets during scaling. The trend on the enterprise value chart allows for an assessment of the quality of financial management.